Effect of Proton-Pump Inhibitor Therapy on Serum Chromogranin A Level
暂无分享,去创建一个
Z. Tulassay | K. Rácz | A. Patócs | P. Miheller | M. Juhász | L. Herszényi | I. Hritz | I. Pregun
[1] W. Jeske,et al. Commentary to “Chromogranin A: Biological Function and Clinical Utility in Neuroendocrine Tumor Disease” , 2010, Annals of surgical oncology.
[2] I. Modlin,et al. Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease , 2010, Annals of Surgical Oncology.
[3] P. Moayyedi,et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. , 2010, The Cochrane database of systematic reviews.
[4] C. Reimer,et al. Clinical trial: long‐term use of proton pump inhibitors in primary care patients – a cross sectional analysis of 901 patients , 2009, Alimentary pharmacology & therapeutics.
[5] C. Reimer,et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. , 2009, Gastroenterology.
[6] Z. Tulassay,et al. Peptic Esophageal Stricture: Medical Treatment , 2009, Digestive Diseases.
[7] P. Orosz,et al. Gastroesophageal Reflux Disease: Work-Related Disease? , 2009, Digestive Diseases.
[8] P. Igaz,et al. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment. , 2009, European journal of gastroenterology & hepatology.
[9] H. Chae,et al. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin]. , 2009, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[10] G. Qvigstad,et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition , 2008, Scandinavian journal of gastroenterology.
[11] B. Hirschowitz,et al. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia , 2007, Alimentary pharmacology & therapeutics.
[12] H. El‐Serag,et al. Temporal trends in new and recurrent oesophageal strictures in a Medicare population , 2007, Alimentary pharmacology & therapeutics.
[13] G. Cui,et al. Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. , 2007, World journal of gastroenterology.
[14] P. Moayyedi,et al. Diagnostic and Therapeutic Use of Proton Pump Inhibitors in Non-Cardiac Chest Pain: A Metaanalysis , 2005, The American Journal of Gastroenterology.
[15] J. Zacny,et al. Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients , 2005, Alimentary pharmacology & therapeutics.
[16] D. Conte,et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. , 2005, European journal of endocrinology.
[17] J. Sen,et al. Chromogranin A, a Marker of the Therapeutic Success of Resection of Neuroendocrine Liver Metastases: Preliminary Report , 2004, World Journal of Surgery.
[18] E. van Marck,et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. , 2004, Diabetes care.
[19] F. Minuto,et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. , 2004, European journal of endocrinology.
[20] G. Qvigstad,et al. Hypergastrinemia in animals and man: causes and consequences , 2004, Scandinavian journal of gastroenterology.
[21] M. Stridsberg,et al. A comparison between three commercial kits for chromogranin A measurements. , 2003, The Journal of endocrinology.
[22] R. Jensen,et al. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. , 2002, Pharmacology & toxicology.
[23] D. Jonkers,et al. Serum chromogranin A as a screening test for gastric enterochromaffin‐like cell hyperplasia during acid‐suppressive therapy , 2001, European journal of clinical investigation.
[24] D. O'Connor,et al. Malignant Pheochromocytoma: Chromaffin Granule Transmitters and Response to Treatment , 2000, Hypertension.
[25] A. Kjellin,et al. Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders , 2000, Alimentary pharmacology & therapeutics.
[26] Jonkers,et al. Serum gastrin and chromogranin A during medium‐ and long‐term acid suppressive therapy: a case‐control study , 1999, Alimentary pharmacology & therapeutics.
[27] J. Rehfeld,et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. , 1997, Scandinavian journal of gastroenterology.
[28] A. Sandvik,et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. , 1996, Gut.
[29] J. Jansen,et al. Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety , 1994, Annals of Internal Medicine.
[30] A. Sandvik,et al. Gastrin-histamine sequence in the regulation of gastric acid secretion. , 1991, Gut.
[31] G. Dockray,et al. Gastrin: old hormone, new functions , 2004, Pflügers Archiv.
[32] J. C. Tony. The chromogranin-secretogranin family. , 2003, The New England journal of medicine.
[33] A. Oluwasanmi,et al. Gastro-oesophageal reflux disease. , 1999, Hospital medicine.